cancer

U.S. cancer centers are moving quickly to enroll patients in an expanded access program for a pancreatic cancer drug developed by Revolution Medicines Inc. (NASDAQ:RVMD) after clinical trial results showed the treatment significantly extended survival in patients with advanced disease. • ...

Protara Therapeutics Inc. (NASDAQ:TARA) reported updated 12-month Phase 2 data for TARA-002 in patients with Bacillus Calmette-Guérin (BCG)-naïve non-muscle invasive bladder cancer (NMIBC), highlighting durable complete response rates and a favorable safety profile. The updated findings from Cohort...

Oncolytics Biotech, Inc. (NASDAQ:ONCY) shares are up on Monday as the company reported promising durability data for its investigational immunotherapy, pelareorep, in treating metastatic colorectal cancer. • Oncolytics Biotech shares are powering higher. What’s behind ONCY gains?...

Inhibrx Biosciences Inc. (NASDAQ:INBX) is attracting interest from major drugmakers for its experimental cancer therapy INBRX-106, which could be valued at over $8 billion. • Inhibrx Biosciences stock is challenging resistance. Why did INBX hit a new high? The cancer-focused biotech is...

Waters Corporation (NYSE:WAT) shares are up on Wednesday as the company announced FDA clearance for its Onclarity HPV Self-Collection Kit, a significant step in expanding access to cervical cancer screening. • Waters stock is showing exceptional strength. What’s fueling WAT momentum?...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) shares are down on Tuesday as the company announced broad alignment with the FDA regarding the registration path for its CRB-701 treatment. • Corbus Pharmaceuticals stock is showing weakness. What’s driving CRBP stock lower? FDA...

The U.S. Food and Drug Administration (FDA) on Friday approved Bristol Myers Squibb & Co.’s (NYSE:BMY) Opdivo (nivolumab) with chemotherapy for untreated Hodgkin lymphoma, one of the most curable forms of cancer, with high long-term survival rates, particularly when detected early...

Novartis AG (NYSE:NVS) on Friday agreed to acquire a next-generation PI3Kα inhibitor program from Synnovation Therapeutics, aiming to strengthen its breast cancer pipeline with a more targeted and potentially better-tolerated treatment approach. • Novartis stock is taking a breather. What...

AIM ImmunoTech Inc. (AMEX:AIM) shares moved higher on Wednesday after the company secured full approval for a key cancer-related patent in Japan. • AIM ImmunoTech stock is showing exceptional strength. Why are AIM shares rallying? The development strengthens its intellectual property position...

ImmunityBio Inc. (NASDAQ:IBRX) shares are up on Monday following the company’s announcement of significant revenue growth. • ImmunityBio stock is challenging resistance. Why are IBRX shares at highs? The stock has jumped around 55% over the last month, thanks to investor interest after...

Johnson & Johnson (NYSE:JNJ) shared topline results from the investigational Phase 3 MajesTEC-9 study of Tecvayli (teclistamab-cqyv) monotherapy for multiple myeloma, a type of blood cancer. The MajesTEC-9 study evaluates the efficacy and safety of Tecvayli versus the standard of care of...

Erasca Inc. (NASDAQ:ERAS) shares on Wednesday jumped close to 60% to $6.12. On Thursday, the stock fell as low as $4.33. • Erasca shares are advancing steadily. Why is ERAS stock trading higher? The movement came in reaction to a rumored deal, wherein AbbVie Inc. (NYSE:ABBV) was reportedly...

Johnson & Johnson (NYSE:JNJ) has been directed to pay $65.6 million to a Minnesota woman who was diagnosed with cancer following the use of their talcum powder. What Happened: A Minnesota jury awarded Anna Jean Houghton Carley, a mother of three, $65.5 million on Friday. Carley contended...

Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. • Merck & Co stock is showing upward bias. What’s...

Arcus Biosciences, Inc. (NYSE:RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc. (NASDAQ:GILD), due to futility. • Arcus Biosciences stock is among today’s weakest performers. Why is RCUS stock dropping...